Reimbursed Care Access in France

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized routine medical use outside of approved clinical research. Clinical access in France is therefore only possible through authorised clinical trials or exceptional regulatory pathways under ANSM oversight; sponsors must request explicit ANSM authorisation for any trial involving stupéfiants and comply with stringent storage, security and import/export conditions #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Any investigational use of MDMA in France requires ANSM authorisation for clinical trials and adherence to national rules on handling of stupéfiants for research. Sponsors must follow ANSM procedures for authorisation and the security rules applicable to controlled substances used in trials #.

Esketamine (nasal formulation SPRAVATO and injectable esketamine products) is an authorised medicinal product in France and has been the subject of formal HAS evaluations and reimbursement opinions. HAS issued a favourable opinion for reimbursement of SPRAVATO (eskétamine) in combination with an SSRI/SNRI for adults under 65 with treatment‑resistant major depressive episodes who have failed at least two antidepressants during the current episode, or when ECT is contraindicated, refused, or not accessible #. HAS has also published multiple opinions and re‑evaluations for esketamine injectable products (ESKESIA, ESKETAMINE RENAUDIN) addressing anaesthesia and specific indications with associated reimbursement decisions #; #.

Reimbursement and access details: HAS recommendations define the clinical indication(s) eligible for reimbursement and the clinical context (specialist involvement, concomitant antidepressant). Where HAS has given a favourable reimbursement opinion for a precise indication, national health insurance (Assurance Maladie) may cover the treatment according to the conditions set by HAS (indication limits, patient selection). Practically, access is limited to the approved, labelled indications and subject to hospital or ambulatory dispensing rules set out in the marketing authorisation and HAS opinion #.

Ketamine is an authorised medicinal product in France principally indicated and used as an anaesthetic agent; ampoule injectable forms are listed under controlled substance rules and reserved for hospital use with strict prescription and storage obligations. The product monographs and national recommendations describe ketamine as an anaesthetic (induction and maintenance) and note well‑defined hospital uses; two hospital‑use/off‑label analgesic situations (e.g., palliative refractory pain and certain postoperative analgesia contexts) are described in national guidance, but prolonged outpatient prescribing is not standard and is actively monitored by ANSM because of safety signals (hepatic, urinary) with prolonged use #; #.

Regulatory and reimbursement context: ketamine formulations authorised for anaesthesia are hospital medicines (Liste I or stupéfiants depending on preparation) and are not part of routine ambulatory reimbursed psychotherapeutic programmes; any use outside MA (e.g., prolonged analgesic regimens or psychiatric uses) is considered off‑label, must follow local/academic recommendations, and is subject to pharmacovigilance and addictovigilance oversight #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Any investigational DMT programme in France would require prior ANSM authorisation for use of stupéfiants in trials and compliance with security/storage obligations #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Use in France is limited to authorised clinical trials with ANSM approval and strict fulfillment of the regulatory and security requirements for stupéfiants in research #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Any clinical investigation involving ibogaine must obtain ANSM authorisation and comply with the national rules governing use of stupéfiants in clinical trials and the special safety monitoring required #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ritual or non‑medical use is not authorised in France and possession/supply of preparations containing controlled tryptamines is illegal; clinical research would require ANSM authorisation governed by the regulatory framework for stupéfiants in trials #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Any investigational use would require ANSM authorisation under the national procedures for clinical trials involving stupéfiants #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Possession, distribution or use outside of authorised research is illegal; any research use requires ANSM authorisation and adherence to the regulatory/security obligations for stupéfiants in clinical trials #.